CIDeCAR

N/A

Report date: 2023/11/01 20:08:59

Base Information

Drug NameCIDeCAR

Drug Alias Nameanti-HER2 CAR T-cell therapy

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsOsteosarcoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBellicum Pharmaceuticals Inc National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals Inc National Cancer Institute

Inactive CompaniesN/A

Active IndicationsOsteosarcoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A